Although appropriate biomarkers for routine clinical use in the prognostic evaluation of patients with MGM remain to be characterized and will involve a complex process of validation, the findings reviewed here indicate that RTKs, particularly EGFR and other members of the ErbB family, as well as HB-EGF and NRG4 (ligands of ErbB1 and ErbB4, respectively), should be further investigated as biomarkers that are potentially capable of aiding in the early detection and determination of tumor grade and prediction of the clinical outcome upon investigation of surgically removed MGM tumors. This evidence concerns the gene EGFR and neoplasm.